Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05827016




Registration number
NCT05827016
Ethics application status
Date submitted
11/04/2023
Date registered
24/04/2023
Date last updated
7/11/2024

Titles & IDs
Public title
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Scientific title
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)
Secondary ID [1] 0 0
2022-501515-14
Secondary ID [2] 0 0
IM048-022
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Iberdomide
Treatment: Drugs - Lenalidomide

Experimental: Arm A1: Iberdomide Dose 1 -

Experimental: Arm A2: Iberdomide Dose 2 -

Experimental: Arm A3: Iberdomide Dose 3 -

Active comparator: Arm B: Lenalidomide -


Treatment: Drugs: Iberdomide
Specified dose on specified days

Treatment: Drugs: Lenalidomide
Specified dose on specified days
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free survival (PFS)
Timepoint [1] 0 0
Up to 6 years
Secondary outcome [1] 0 0
Achieving minimal residual disease (MRD) negativity in participants with complete response (CR) or better at 12 (± 3) months of maintenance treatment
Timepoint [1] 0 0
Up to 6 years
Secondary outcome [2] 0 0
Overall Survival
Timepoint [2] 0 0
Up to 12 years
Secondary outcome [3] 0 0
Recommended iberdomide dose for Stage 2
Timepoint [3] 0 0
Up to 1 year
Secondary outcome [4] 0 0
Area under the iberdomide plasma concentration-time curve from time zero to tau
Timepoint [4] 0 0
Up to 1 year
Secondary outcome [5] 0 0
Area under the iberdomide plasma concentration-time curve within a dosing interval AUC (TAU)
Timepoint [5] 0 0
Up to 1 year
Secondary outcome [6] 0 0
Maximum iberdomide concentration (Cmax)
Timepoint [6] 0 0
Up to 1 year
Secondary outcome [7] 0 0
Time to maximum iberdomide plasma concentration (Tmax)
Timepoint [7] 0 0
Up to 1 year
Secondary outcome [8] 0 0
Number of participants with adverse events (AEs)
Timepoint [8] 0 0
Up to 6 years
Secondary outcome [9] 0 0
Progression-free survival on next line of treatment (PFS2)
Timepoint [9] 0 0
Up to 6 years
Secondary outcome [10] 0 0
Achieving MRD negativity in participants with CR or better at any time after the date of randomization
Timepoint [10] 0 0
Up to 6 years
Secondary outcome [11] 0 0
Conversion from MRD positive to MRD negative in participants with CR or better
Timepoint [11] 0 0
Up to 6 years
Secondary outcome [12] 0 0
Achievement of CR or better and maintaining MRD-negative status in 2 bone marrow aspirate assessments that are a minimum of 6 months or 1 year apart, without any examination showing MRD positive status in between assessments
Timepoint [12] 0 0
Up to 6 years
Secondary outcome [13] 0 0
Time to progression (TTP)
Timepoint [13] 0 0
Up to 6 years
Secondary outcome [14] 0 0
Time to next treatment (TTNT)
Timepoint [14] 0 0
Up to 6 years
Secondary outcome [15] 0 0
Best response achieved prior to progressive disease (PD)
Timepoint [15] 0 0
Up to 6 years
Secondary outcome [16] 0 0
Patient-reported health-related quality of life (HRQoL) outcomes and multiple myeloma-related symptoms as measured by the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life C30 questionnaire (QLQ-C30)
Timepoint [16] 0 0
Up to 6 years
Secondary outcome [17] 0 0
Patient-reported HRQoL outcomes and multiple myeloma-related symptoms as measured by the EORTC Quality of Life Multiple Myeloma Module (QLQ-MY20)
Timepoint [17] 0 0
Up to 6 years

Eligibility
Key inclusion criteria
Inclusion Criteria

* Confirmed diagnosis of symptomatic multiple myeloma (MM).
* Eastern Cooperative Oncology Group performance status (ECOG) score of 0, 1, or 2.
* Received 3 to 6 cycles of an induction therapy that includes a proteasome inhibitor (PI) and immunomodulatory (IMiD) [eg, bortezomib thalidomide and dexamethasone (VTd), lenalidomide, bortezomib and dexamethasone (RVd)] with or without a CD38 monoclonal antibody, or Velcade® (bortezomib), cyclophosphamide, dexamethasone (VCd), and followed by a single or tandem autologous stem cell transplantation (ASCT). Post-stem cell transplant consolidation is permitted.
* Participants within 12 months from initiation of induction therapy who achieved at least a partial response (PR) after autologous stem cell transplantation (ASCT) with or without consolidation, according to International Myeloma Working Group (IMWG 2016) criteria.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* Progressive disease or clinical relapse (as defined by IMWG response criteria) following ASCT with or without consolidation or is not responsive to primary therapy.
* Smoldering myeloma, solitary plasmacytoma or nonsecretory myeloma.
* Known central nervous system/meningeal involvement of MM.
* Prior history of malignancies, other than MM, unless the participant has been free of the disease for = 5 years.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/06/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/01/2036
Actual
Sample size
Target
1216
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Calvary Mater Newcastle - Waratah
Recruitment hospital [2] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [3] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [4] 0 0
Monash Health - Clayton
Recruitment postcode(s) [1] 0 0
2298 - Waratah
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment postcode(s) [3] 0 0
3128 - Box Hill
Recruitment postcode(s) [4] 0 0
3800 - Clayton
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Colorado
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Mississippi
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Oregon
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Tennessee
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
Argentina
State/province [20] 0 0
B
Country [21] 0 0
Argentina
State/province [21] 0 0
Caba
Country [22] 0 0
Argentina
State/province [22] 0 0
Córdoba
Country [23] 0 0
Austria
State/province [23] 0 0
Linz
Country [24] 0 0
Austria
State/province [24] 0 0
St. Pölten
Country [25] 0 0
Austria
State/province [25] 0 0
Vienna
Country [26] 0 0
Belgium
State/province [26] 0 0
WHT
Country [27] 0 0
Belgium
State/province [27] 0 0
Kortrijk
Country [28] 0 0
Brazil
State/province [28] 0 0
PR
Country [29] 0 0
Brazil
State/province [29] 0 0
RJ
Country [30] 0 0
Brazil
State/province [30] 0 0
SP
Country [31] 0 0
Brazil
State/province [31] 0 0
Barretos
Country [32] 0 0
Brazil
State/province [32] 0 0
Porto Alegre
Country [33] 0 0
Brazil
State/province [33] 0 0
Rio de Janeiro
Country [34] 0 0
Brazil
State/province [34] 0 0
Salvador
Country [35] 0 0
Canada
State/province [35] 0 0
Alberta
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec
Country [38] 0 0
Chile
State/province [38] 0 0
Santiago
Country [39] 0 0
Chile
State/province [39] 0 0
Temuco
Country [40] 0 0
Chile
State/province [40] 0 0
Vitacura
Country [41] 0 0
China
State/province [41] 0 0
AH
Country [42] 0 0
China
State/province [42] 0 0
Beijing
Country [43] 0 0
China
State/province [43] 0 0
Chongqing
Country [44] 0 0
China
State/province [44] 0 0
Guangdong
Country [45] 0 0
China
State/province [45] 0 0
Henan
Country [46] 0 0
China
State/province [46] 0 0
Hunan
Country [47] 0 0
China
State/province [47] 0 0
Jiangsu
Country [48] 0 0
China
State/province [48] 0 0
Jiangxi
Country [49] 0 0
China
State/province [49] 0 0
Jilin
Country [50] 0 0
China
State/province [50] 0 0
Liaoning
Country [51] 0 0
China
State/province [51] 0 0
Shaanxi
Country [52] 0 0
China
State/province [52] 0 0
Shandong
Country [53] 0 0
China
State/province [53] 0 0
Shanghai
Country [54] 0 0
China
State/province [54] 0 0
Tianjin
Country [55] 0 0
China
State/province [55] 0 0
Zhejiang
Country [56] 0 0
China
State/province [56] 0 0
Changsha
Country [57] 0 0
China
State/province [57] 0 0
Fuzhou
Country [58] 0 0
China
State/province [58] 0 0
Guangzhou
Country [59] 0 0
China
State/province [59] 0 0
Jinan
Country [60] 0 0
China
State/province [60] 0 0
Nanjing
Country [61] 0 0
China
State/province [61] 0 0
Qingdao
Country [62] 0 0
China
State/province [62] 0 0
Suzhou Shi
Country [63] 0 0
China
State/province [63] 0 0
Wenzhou Shi
Country [64] 0 0
China
State/province [64] 0 0
Wuhan Shi
Country [65] 0 0
China
State/province [65] 0 0
Wuhan
Country [66] 0 0
Colombia
State/province [66] 0 0
COR
Country [67] 0 0
Colombia
State/province [67] 0 0
Bogota
Country [68] 0 0
Colombia
State/province [68] 0 0
Floridablanca
Country [69] 0 0
Colombia
State/province [69] 0 0
Medellin
Country [70] 0 0
Colombia
State/province [70] 0 0
Valledupar
Country [71] 0 0
Czechia
State/province [71] 0 0
Brno
Country [72] 0 0
Czechia
State/province [72] 0 0
Olomouc
Country [73] 0 0
Czechia
State/province [73] 0 0
Prague
Country [74] 0 0
Czechia
State/province [74] 0 0
Praha
Country [75] 0 0
Denmark
State/province [75] 0 0
Odense
Country [76] 0 0
Finland
State/province [76] 0 0
Helsinki
Country [77] 0 0
Finland
State/province [77] 0 0
Kuopio
Country [78] 0 0
France
State/province [78] 0 0
Amiens Cedex 1
Country [79] 0 0
France
State/province [79] 0 0
Caen
Country [80] 0 0
France
State/province [80] 0 0
Creteil
Country [81] 0 0
France
State/province [81] 0 0
La Roche Sur Yon
Country [82] 0 0
France
State/province [82] 0 0
Lille
Country [83] 0 0
France
State/province [83] 0 0
Limoges
Country [84] 0 0
France
State/province [84] 0 0
Nantes
Country [85] 0 0
France
State/province [85] 0 0
Paris
Country [86] 0 0
France
State/province [86] 0 0
Toulouse
Country [87] 0 0
Germany
State/province [87] 0 0
BE
Country [88] 0 0
Germany
State/province [88] 0 0
BW
Country [89] 0 0
Germany
State/province [89] 0 0
BY
Country [90] 0 0
Germany
State/province [90] 0 0
Hamburg
Country [91] 0 0
Germany
State/province [91] 0 0
Hamm
Country [92] 0 0
Germany
State/province [92] 0 0
Jena
Country [93] 0 0
Germany
State/province [93] 0 0
Tübingen
Country [94] 0 0
Greece
State/province [94] 0 0
B
Country [95] 0 0
Greece
State/province [95] 0 0
G
Country [96] 0 0
Greece
State/province [96] 0 0
I
Country [97] 0 0
Greece
State/province [97] 0 0
Athens
Country [98] 0 0
Greece
State/province [98] 0 0
Larisa
Country [99] 0 0
Greece
State/province [99] 0 0
Thessaloniki
Country [100] 0 0
Hong Kong
State/province [100] 0 0
HK
Country [101] 0 0
Hungary
State/province [101] 0 0
HB
Country [102] 0 0
India
State/province [102] 0 0
CH
Country [103] 0 0
India
State/province [103] 0 0
Karnataka
Country [104] 0 0
India
State/province [104] 0 0
KL
Country [105] 0 0
India
State/province [105] 0 0
MH
Country [106] 0 0
India
State/province [106] 0 0
Odisha
Country [107] 0 0
India
State/province [107] 0 0
WB
Country [108] 0 0
India
State/province [108] 0 0
Navi Mumbai
Country [109] 0 0
Israel
State/province [109] 0 0
Ashdod
Country [110] 0 0
Israel
State/province [110] 0 0
Beer Ya'Aqov
Country [111] 0 0
Israel
State/province [111] 0 0
Hadera
Country [112] 0 0
Israel
State/province [112] 0 0
Haifa
Country [113] 0 0
Israel
State/province [113] 0 0
Jerusalem
Country [114] 0 0
Israel
State/province [114] 0 0
Petah Tikva
Country [115] 0 0
Israel
State/province [115] 0 0
Ramat Gan
Country [116] 0 0
Israel
State/province [116] 0 0
Tel Aviv-Yafo
Country [117] 0 0
Italy
State/province [117] 0 0
CT
Country [118] 0 0
Italy
State/province [118] 0 0
FL
Country [119] 0 0
Italy
State/province [119] 0 0
GE
Country [120] 0 0
Italy
State/province [120] 0 0
MI
Country [121] 0 0
Italy
State/province [121] 0 0
PI
Country [122] 0 0
Italy
State/province [122] 0 0
RM
Country [123] 0 0
Italy
State/province [123] 0 0
TO
Country [124] 0 0
Italy
State/province [124] 0 0
Naples
Country [125] 0 0
Italy
State/province [125] 0 0
Pavia
Country [126] 0 0
Italy
State/province [126] 0 0
Rome
Country [127] 0 0
Japan
State/province [127] 0 0
Kanagawa
Country [128] 0 0
Japan
State/province [128] 0 0
Kumamoto
Country [129] 0 0
Japan
State/province [129] 0 0
Chiba-shi
Country [130] 0 0
Japan
State/province [130] 0 0
Gifu-Shi
Country [131] 0 0
Japan
State/province [131] 0 0
Higashiibaraki-Gun
Country [132] 0 0
Japan
State/province [132] 0 0
Hiroshima-shi
Country [133] 0 0
Japan
State/province [133] 0 0
Isehara-shi
Country [134] 0 0
Japan
State/province [134] 0 0
Kagoshima-Shi
Country [135] 0 0
Japan
State/province [135] 0 0
Kanazawa-shi
Country [136] 0 0
Japan
State/province [136] 0 0
Kobe-Shi
Country [137] 0 0
Japan
State/province [137] 0 0
Koto-Ku
Country [138] 0 0
Japan
State/province [138] 0 0
Maebashi-Shi
Country [139] 0 0
Japan
State/province [139] 0 0
Minato-ku
Country [140] 0 0
Japan
State/province [140] 0 0
Nagasaki-Shi
Country [141] 0 0
Japan
State/province [141] 0 0
Nagoya-Shi
Country [142] 0 0
Japan
State/province [142] 0 0
Osakasayama-shi
Country [143] 0 0
Japan
State/province [143] 0 0
Saitama-shi
Country [144] 0 0
Japan
State/province [144] 0 0
Sapporo-shi
Country [145] 0 0
Japan
State/province [145] 0 0
Sendai-shi
Country [146] 0 0
Japan
State/province [146] 0 0
Shibukawa-shi
Country [147] 0 0
Japan
State/province [147] 0 0
Shibuya-ku
Country [148] 0 0
Japan
State/province [148] 0 0
Shizuoka-shi
Country [149] 0 0
Korea, Republic of
State/province [149] 0 0
Busan
Country [150] 0 0
Korea, Republic of
State/province [150] 0 0
Goyang-si
Country [151] 0 0
Korea, Republic of
State/province [151] 0 0
Seongnam-si, Gyeonggi-do
Country [152] 0 0
Korea, Republic of
State/province [152] 0 0
Seoul
Country [153] 0 0
Korea, Republic of
State/province [153] 0 0
Ulsan
Country [154] 0 0
Mexico
State/province [154] 0 0
CMX
Country [155] 0 0
Mexico
State/province [155] 0 0
MEX
Country [156] 0 0
Mexico
State/province [156] 0 0
NL
Country [157] 0 0
Mexico
State/province [157] 0 0
Mexico city
Country [158] 0 0
Netherlands
State/province [158] 0 0
NH
Country [159] 0 0
Netherlands
State/province [159] 0 0
Dordrecht
Country [160] 0 0
Poland
State/province [160] 0 0
KP
Country [161] 0 0
Poland
State/province [161] 0 0
LD
Country [162] 0 0
Poland
State/province [162] 0 0
PM
Country [163] 0 0
Poland
State/province [163] 0 0
Gliwice
Country [164] 0 0
Poland
State/province [164] 0 0
Katowice
Country [165] 0 0
Poland
State/province [165] 0 0
Lublin
Country [166] 0 0
Poland
State/province [166] 0 0
Warsaw
Country [167] 0 0
Portugal
State/province [167] 0 0
Braga
Country [168] 0 0
Portugal
State/province [168] 0 0
Coimbra
Country [169] 0 0
Portugal
State/province [169] 0 0
Porto
Country [170] 0 0
Romania
State/province [170] 0 0
B
Country [171] 0 0
Romania
State/province [171] 0 0
Dolj
Country [172] 0 0
Romania
State/province [172] 0 0
IS
Country [173] 0 0
Romania
State/province [173] 0 0
Jud. Cluj
Country [174] 0 0
Romania
State/province [174] 0 0
Cluj-Napoca
Country [175] 0 0
Singapore
State/province [175] 0 0
Singapore
Country [176] 0 0
Spain
State/province [176] 0 0
Asturias
Country [177] 0 0
Spain
State/province [177] 0 0
B
Country [178] 0 0
Spain
State/province [178] 0 0
CC
Country [179] 0 0
Spain
State/province [179] 0 0
Las Palmas
Country [180] 0 0
Spain
State/province [180] 0 0
MU
Country [181] 0 0
Spain
State/province [181] 0 0
VC
Country [182] 0 0
Spain
State/province [182] 0 0
Badalona
Country [183] 0 0
Spain
State/province [183] 0 0
Palma de Mallorca
Country [184] 0 0
Spain
State/province [184] 0 0
Pamplona
Country [185] 0 0
Sweden
State/province [185] 0 0
BD
Country [186] 0 0
Sweden
State/province [186] 0 0
Borås
Country [187] 0 0
Sweden
State/province [187] 0 0
Uddevalla
Country [188] 0 0
Switzerland
State/province [188] 0 0
Aarau 1
Country [189] 0 0
Taiwan
State/province [189] 0 0
Kao-Hsiung
Country [190] 0 0
Taiwan
State/province [190] 0 0
Kaohsiung
Country [191] 0 0
Taiwan
State/province [191] 0 0
New Taipei City
Country [192] 0 0
Taiwan
State/province [192] 0 0
Tainan
Country [193] 0 0
Taiwan
State/province [193] 0 0
Taipei
Country [194] 0 0
Taiwan
State/province [194] 0 0
Taoyuan
Country [195] 0 0
Turkey
State/province [195] 0 0
Ankara
Country [196] 0 0
Turkey
State/province [196] 0 0
Cankaya
Country [197] 0 0
Turkey
State/province [197] 0 0
Edirne
Country [198] 0 0
Turkey
State/province [198] 0 0
Istanbul
Country [199] 0 0
Turkey
State/province [199] 0 0
Izmir
Country [200] 0 0
Turkey
State/province [200] 0 0
Kayseri
Country [201] 0 0
Turkey
State/province [201] 0 0
Yenimahalle
Country [202] 0 0
United Kingdom
State/province [202] 0 0
ABD
Country [203] 0 0
United Kingdom
State/province [203] 0 0
Berkshire
Country [204] 0 0
United Kingdom
State/province [204] 0 0
DBY
Country [205] 0 0
United Kingdom
State/province [205] 0 0
DOR
Country [206] 0 0
United Kingdom
State/province [206] 0 0
HAM
Country [207] 0 0
United Kingdom
State/province [207] 0 0
Staffordshire
Country [208] 0 0
United Kingdom
State/province [208] 0 0
Edinburgh
Country [209] 0 0
United Kingdom
State/province [209] 0 0
London
Country [210] 0 0
United Kingdom
State/province [210] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Trial website
https://clinicaltrials.gov/study/NCT05827016
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Address 0 0
Country 0 0
Phone 0 0
855-907-3286
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05827016